Perfusion Medical is an emerging biopharmaceutical company developing life-saving cardiovascular therapies focused on shock and ischemic conditions. Its lead candidate, PM-208, is a first-in-class critical care therapy with an initial focus on hemorrhagic shock, a leading cause of preventable death after trauma. Backed by 22 preclinical studies, the company will file its IND in June 2026. A fully funded Phase 1 human clinical trial will follow.